Consolidated Note 2025 2024 $ $ Income Other income 4 2,829,333 2,407,206 Net (loss) on investment at fair value through profit and loss 7 465,361 1,047,771 Expenses Corporate administration expenses 5 (938,917) (1,099,009) Research and development expenses (4,266,476) (2,935,087) Depreciation and amortisation expenses (1,743) (1,743) Consulting, employee & director expenses 5 (3,000,268) (2,966,095) Finance costs 5 (503,460) (31,160) Fair value movement in derivative liability 9 532,000 - Loss before income tax expense (4,884,170) (3,578,117) Income tax expense - - - Loss after income tax expense for the year attributable to the owners of Noxopharm Limited (4,884,170) (3,578,117) Other comprehensive income for the year, net of tax - - Total comprehensive income for the year attributable to the owners of Noxopharm Limited (4,884,170) (3,578,117) Cents Cents Basic earnings per share 24 (1.67) (1.22) Diluted earnings per share 24 (1.67) (1.22) Statement of profit or loss and other comprehensive income For the year ended 30 June 2025 Annual Report 2025 25
RkJQdWJsaXNoZXIy MjE2NDg3